drugset / Trial / NCT01037478
Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether Resminostat (4SC-201) is effective and safe in the treatment of relapsed or refractory Hodgkin's Lymphoma.
Timeline
- Start
- 2009-12
- Primary completion
- 2012-01
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Resminostat | Small molecule | — | Oral |